Publications by authors named "Aruna Muthukumar"
Introduction: Ivacaftor (IVA) has been shown to change the trajectory of cystic fibrosis (CF) disease progression by slowing the rate of lung function decline in clinical studies. Long-term real-world data help to confirm the durability of this response.
Methods: This non-interventional, longitudinal study used data from the US CF Foundation Patient Registry to describe the annualized rate of change in lung function in people with CF receiving IVA.
Background: Herpes zoster (HZ) is a painful condition caused by reactivation of the varicella-zoster virus. The objectives of this study were to compare HZ incidence in adults with asthma versus adults without asthma and to compare healthcare resource use as well as direct costs in adults with HZ and asthma versus adults with asthma alone in the USA.
Methods: This retrospective longitudinal cohort study included adults aged ≥18 years across the USA.
Background: Ivacaftor (IVA) improves lung function and other extrapulmonary outcomes in people with cystic fibrosis (CF). However, the effect of initiating IVA at earlier versus later ages has not been studied.
Methods: We conducted an observational cohort study of people in the US CF Foundation Patient Registry aged ≥6 years with ≥1 CF transmembrane conductance regulator-gating mutation to compare the effects of initiating IVA at earlier ages on per cent predicted forced expiratory volume in 1 s (ppFEV) and pulmonary exacerbation (PEx) outcomes.
Article Synopsis
- The study investigates real-world treatment practices and outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC) who have specific gene mutations related to DNA repair.
- Among 138 patients analyzed, common mutations included CDK12, BRCA2, and ATM; novel hormonal treatments and taxane chemotherapy were mainly used for first-line therapy, with survival rates declining in subsequent treatment lines.
- Findings suggest that treatment patterns for mCRPC patients are consistent with existing literature, regardless of the presence of homologous recombination repair (HRR) mutations.
Objective: To evaluate the associations between 10 well-established ovarian cancer risk factors and risk of ovarian cancer among women with vs. without endometriosis.
Design: Pooled analysis of 9 case-control studies in the Ovarian Cancer Association Consortium.
Article Synopsis
- The study aimed to estimate the prevalence of pericarditis, an inflammation of the heart's lining, in the U.S. from 2007 to 2016 to assess its impact on healthcare.
- Using data from three national surveys, researchers calculated an annualized prevalence rate, finding an estimated 160,000 cases in 2020 based on extrapolated population data.
- The findings suggest that pericarditis is a rare condition in the U.S., with significantly fewer than 200,000 affected individuals, despite some limitations in the research methods.
Objective: To evaluate the association between hysterectomy and ovarian cancer, and to understand how hormone therapy (HT) use and endometriosis affect this association.
Methods: We conducted a pooled analysis of self-reported data from 11 case-control studies in the Ovarian Cancer Association Consortium (OCAC). Women with (n = 5350) and without ovarian cancer (n = 7544) who never used HT or exclusively used either estrogen-only therapy (ET) or estrogen+progestin therapy (EPT) were included.